Nanalysis Announces First Quarter 2026 Results
Nanalysis Announces First Quarter 2026 Results |
| [20-May-2026] |
Reports Quarterly Revenue of $10.7 Million and Adjusted EBITDA of $292 Thousand CALGARY, AB, May 20, 2026 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications, announces its financial results for the first quarter ending March 31, 2026. Chief Executive Officer Sean Krakiwsky and Interim Chief Financial Officer Heather Kury will host a conference call at 10 A.M. Eastern Time tomorrow to discuss the results. All interested parties are invited to join the call through the details provided below. All dollar figures in this press release are in thousands of Canadian dollars, except per share amounts or unless otherwise stated. The Company reported first quarter revenue of $10.7 million, consistent with both the prior quarter and the comparative period in 2025. The Company also delivered Adjusted EBITDA of $292 thousand, continuing its trend of positive EBITDA, and representing an increase of $112 thousand over the comparative period in 2025. "We are encouraged by the operational progress made during the first quarter, particularly within our Security Services segment where margin performance improved meaningfully year-over year," said Sean Krakiwsky, Founder and CEO of Nanalysis. "While scientific equipment purchasing activity continues to experience longer sales cycles in certain markets, we believe the actions taken throughout 2025 to streamline operations, strengthen sales execution and improve efficiency are beginning to positively impact the business. We remain focused on disciplined execution, operational efficiency, and positioning the Company for improved performance through the balance of 2026. Financial highlights for the three months ended March 31, 2026:
Quarterly Trend:
In Q1 2026, product sales decreased by $1,954 from Q4 2025 due to normal seasonality and softer benchtop NMR demand in certain markets. This was partially offset by an increase in Security Services revenue driven by higher project-related activity associated with the Airport Security Maintenance Business. Recent strategic and operational highlights include:
Outlook "Our outlook has not changed, and we continue to expect improved operational performance through 2026." said Mr. Krakiwsky. "We believe the actions taken over the past year to strengthen our operational efficiency and invest in customer and distributor relationships are positioning the Company for improved financial performance over time. While macroeconomic conditions continue to impact purchasing timelines in the Scientific Equipment segment, we remain focused on disciplined execution and long-term value creation across both operating segments. Conference Call: Thursday May 21st, 10am EST Investors interested in participating in the live call can join through Zoom. Details provided below. https://us02web.zoom.us/j/87624958529?pwd=FxTQ2xf1geEDJ3svrWXYSiNBZ7rJ5g.1 Meeting ID: 876 2495 8529 One tap mobile The webcast will be archived on the Company's investor relations webpage for at least 90 days. Non-IFRS and Supplementary Financial Measures The Company prepares and reports its consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, as adopted by the Canadian Accounting Standards Board ("IFRS"). However, the press release may make reference to certain non-IFRS measures includes key performance indicators used by management. These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS The Company uses Adjusted Earnings Before Interest, Tax, Depreciation and Amortization ("Adjusted EBITDA"), which may be calculated differently by other companies. This non-IFRS measure is used to provide investors a supplemental measure of the Company's operating performance and liquidity and thus highlight trends in the Company's business that may not otherwise be apparent when relying solely on IFRS measures. The Company also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of companies in similar industries. Adjusted EBITDA
Supplementary Financial Measures The Company may also use supplementary financial measures which are intended to be disclosed on a periodic basis to depict the historical or expected future financial performance, cash position, or cash flow of the Company, are not a non-IFRS measure, and are not presented in the financial statements. The measures as discussed in this press release include:
About Nanalysis Scientific Corp. (TSXV: NSCI, FRA:1N1) Nanalysis Scientific Corp. develops and manufactures benchtop Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports. Notice regarding Forward Looking Statements and Legal Disclaimer This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
SOURCE Nanalysis Scientific Corp. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Codes: TorontoVE:NSCI,Frankfurt:1N1,OTC-PINK:NSCIF,FRA:1N1,OTC-BB:NSCIF,TorontoV:NSCI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||













